Kilitch Drugs (India) Ltd. (KILITCH): Kilitch Drugs Share Price near 52-week high; stock trades at Rs 225
- September 24, 2026
- Posted by: Harsh Piplani
- Category: News
Kilitch Drugs Share Price is trading at Rs 225, up 0.51% from the previous close, and remains near its 52-week high as of 24 September 2026 at 9:48 AM IST. The company’s market capitalisation stands at Rs 745.38 crore, placing Kilitch Drugs (India) Ltd. in focus among healthcare names on Univest. The latest Univest figures show a session range between Rs 213 and Rs 233.5, with the stock last quoted below the day’s high and above the previous close. On current evidence, the price event is clear, but the data does not establish a company-specific catalyst. For readers tracking Kilitch Drugs Share Price, the market is weighing a near yearly high move against valuation and sector benchmarks in the pharmaceuticals and drugs space.
Kilitch Drugs Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 225 |
| Previous Close | Rs 223.85 |
| Today's Move | +Rs 1.15 (+0.51%) |
| Open | Rs 233.5 |
| High | Rs 233.5 |
| Low | Rs 213 |
| Turnover | Rs 0.11 crore |
| Market Capitalisation | Rs 745.38 crore |
Kilitch Drugs (India) Ltd. (KILITCH) traded at Rs 225 versus the previous close of Rs 223.85, a rise of 0.51%. The stock opened at Rs 233.5, reached a high of Rs 233.5 and touched a low of Rs 213.
Kilitch Drugs Share Price Today shows a modest intraday gain from Rs 223.85 to Rs 225, a change of Rs 1.15. The stock opened at Rs 233.5, matched the day’s high at Rs 233.5, and touched a low of Rs 213 before trading at Rs 225. Turnover stood at Rs 0.11 crore. What happened today is straightforward: the share is holding near its 52-week high while trading within the day’s range after opening above the last quoted level. For investors following Kilitch Drugs Share Price, the key takeaway is that the price event is intact, while the latest Univest data does not identify a stock-specific trigger. Kilitch Drugs Share Price News therefore remains centred on the price position and the nearby yearly high rather than on any stated catalyst.
Kilitch Drugs (India) Ltd. (KILITCH) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 745.38 crore |
| P/E Ratio | 26.04x |
| P/B Ratio | 2.78x |
| ROE | 12.26% |
| ROCE | 14.5% |
| EPS | Rs 8.6 |
| Book Value Per Share | Rs 80.45 |
| Dividend Yield | 0% |
Kilitch Drugs (India) Ltd. (KILITCH) fundamental metrics show P/E 26.04x, P/B 2.78x, ROE 12.26%, ROCE 14.5%. These figures provide context only and are not a buy or sell signal.
Kilitch Drugs (India) Ltd. has a market capitalisation of Rs 745.38 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 26.04x, P/B at 2.78x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.26% and ROCE of 14.5%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 8.6, book value per share of Rs 80.45, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 28.44x, median ROE of 11.69%, median ROCE of 13.32%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 26.04x |
| Benchmark Median P/E | 28.44x |
| Benchmark Average P/E | 42.34x |
| Benchmark P/E Range | 0x to 762.66x |
| Company P/B Ratio | 2.78x |
| Benchmark Median P/B | 3x |
| Company ROE | 12.26% |
| Benchmark Median ROE | 11.69% |
| Company ROCE | 14.5% |
| Benchmark Median ROCE | 13.32% |
| Company Market Capitalisation | Rs 745.38 crore |
| Benchmark Median Market Cap | Rs 777.84 crore |
Kilitch Drugs (India) Ltd. (KILITCH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Kilitch Drugs (India) Ltd. (KILITCH) has a P/E ratio of 26.04x, which is below the benchmark median of 28.44x, a difference of -8.44%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Kilitch Drugs (India) Ltd. (KILITCH) has a ROE of 12.26%, which is above the benchmark median of 11.69%, a difference of +4.88%. Kilitch Drugs (India) Ltd. (KILITCH) has a ROCE of 14.5%, which is above the benchmark median of 13.32%, a difference of +8.86%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Amanta Healthcare Ltd. | AMANTA | 732.71 | 49.93 | 3.28 | 9.4 | 11.23 |
| Zim Laboratories Ltd. | ZIMLAB | 717.41 | 195.34 | 2.48 | 2.14 | 5.47 |
| Wanbury Ltd. | WANBURY | 777.84 | 14.59 | 5.56 | 67.87 | 30.31 |
| Bafna Pharmaceuticals Ltd. | BAFNAPH | 793.67 | 103.94 | 8.41 | 12.27 | 11.87 |
| HEXAGON NUTRITION LIMITED | HEXAGON | 804.13 | 21.21 | 3.32 | 14.11 | 17.37 |
Kilitch Drugs (India) Ltd. (KILITCH) has a P/E ratio of 26.04x compared with the displayed peer median of 49.93x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.26% compares with a peer median of 12.27% across the companies shown in the table. ROCE stood at 14.5% versus the displayed peer median of 11.87%, providing a capital-efficiency comparison. Kilitch Drugs (India) Ltd. (KILITCH) has a market capitalisation of Rs 745.38 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Kilitch Drugs
- Kilitch Drugs Share Price is trading at Rs 225, near its 52-week high, with a Rs 745.38 crore market cap.
- Kilitch Drugs Share Price Today shows a Rs 1.15 rise, or 0.51%, versus the previous close of Rs 223.85.
- The day’s range spans Rs 213 to Rs 233.5, while turnover stands at Rs 0.11 crore.
- Kilitch Drugs Fundamental Analysis shows P/E of 26.04, P/B of 2.78, ROE of 12.26% and ROCE of 14.5%.
- Sector comparison places Kilitch Drugs below the industry median P/E of 28.44 and above the ROE median of 11.69%.
About Kilitch Drugs
Kilitch Drugs (India) Ltd. operates in the healthcare sector and the pharmaceuticals & drugs industry. Kilitch Drugs Share Price is therefore tracked within a segment that is often assessed using valuation ratios, profitability metrics and benchmark comparisons. The company’s latest published numbers include revenue figures, profit figures, EPS, book value and return ratios, which help frame Kilitch Drugs Share Price News in a measurable way. On Univest, this company profile sits alongside the market data that shapes Kilitch Drugs Share Price Today and broader Kilitch Drugs Stock Analysis.
Frequently Asked Questions
Why is Kilitch Drugs Share Price near its 52-week high?
Ans. Kilitch Drugs Share Price is trading at Rs 225, close to its 52-week high, with the latest market capitalisation at Rs 745.38 crore. the latest Univest figures confirm the price event but do not identify a company-specific trigger.
What is Kilitch Drugs Share Price today?
Ans. Kilitch Drugs Share Price Today is Rs 225, up 0.51% from the previous close of Rs 223.85. The stock traded between Rs 213 and Rs 233.5 during the latest observed move.
What does Kilitch Drugs Share Price News show about valuation?
Ans. Kilitch Drugs Share Price News shows a P/E of 26.04 and a P/B of 2.78. Those figures sit below the same-industry medians of 28.44 and 3, respectively, in the latest benchmark set.
How does Kilitch Drugs compare on return ratios?
Ans. Kilitch Drugs Share Price is backed by ROE of 12.26% and ROCE of 14.5%. Both are above the same-industry medians of 11.69% and 13.32%, which gives the stock useful benchmark context.
What is Kilitch Drugs market cap?
Ans. Kilitch Drugs Market Cap stands at Rs 745.38 crore. That is close to the same-industry median market capitalisation of Rs 777.84 crore, so the company sits near the middle of the benchmark range.
What are the key financial figures for Kilitch Drugs?
Ans. Kilitch Drugs Fundamental Analysis includes EPS of Rs 8.6, book value of Rs 80.45 and dividend yield of 0%. Revenue figures and profit figures are also available across recent reporting periods.
How does Kilitch Drugs compare with healthcare peers?
Ans. Kilitch Drugs Share Price compares with peers such as Amanta Healthcare, Zim Laboratories, Wanbury, Bafna Pharmaceuticals and HEXAGON NUTRITION LIMITED. Its valuation sits in the middle of that peer set on the figures shown.
Where can I track Kilitch Drugs Share Price Live?
Ans. You can track Kilitch Drugs Share Price Live on Univest for price updates, market cap, financial ratios, revenue figures and peer comparisons. The platform also keeps the 52-week high context visible for quick reference.
Track Kilitch Drugs Share Price on Univest
Use Kilitch Drugs (India) Ltd. (KILITCH) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
You can track Kilitch Drugs Share Price on Univest for live price updates, market cap, financial ratios, earnings figures, sector context, and the latest market insights. Univest also helps readers follow Kilitch Drugs Stock News, compare valuation with peers, and review the 52-week high context in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
